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Abstract
Hepatic steatosis is a global epidemic that is thought to contribute to the pathogenesis of type 2 diabetes. MicroRNAs
(miRs) are regulators that can functionally integrate a range of metabolic and inflammatory pathways in liver. We aimed to
investigate the functional role of miR-155 in hepatic steatosis. Male C57BL/6 wild-type (WT) and miR-1552/2 mice were fed
either normal chow or high fat diet (HFD) for 6 months then lipid levels, metabolic and inflammatory parameters were
assessed in livers and serum of the mice. Mice lacking endogenous miR-155 that were fed HFD for 6 months developed
increased hepatic steatosis compared to WT controls. This was associated with increased liver weight and serum VLDL/LDL
cholesterol and alanine transaminase (ALT) levels, as well as increased hepatic expression of genes involved in glucose
regulation (Pck1, Cebpa), fatty acid uptake (Cd36) and lipid metabolism (Fasn, Fabp4, Lpl, Abcd2, Pla2g7). Using miRNA target
prediction algorithms and the microarray transcriptomic profile of miR-1552/2 livers, we identified and validated that Nr1h3
(LXRa) as a direct miR-155 target gene that is potentially responsible for the liver phenotype of miR-1552/2 mice. Together
these data indicate that miR-155 plays a pivotal role regulating lipid metabolism in liver and that its deregulation may lead
to hepatic steatosis in patients with diabetes.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is an increasing
health problem in obese individuals in developed countries, and
recent studies suggest an association between the presence of
NAFLD and diabetes risk [1,2]. A spectrum of liver tissue
pathology exists, comprising hepatic steatosis characterized by the
deposition of lipid droplets in hepatocytes, through to non-
alcoholic steatohepatitis (NASH) associated with hepatocyte death,
inflammation and fibrosis. Advanced disease may progress to
cirrhosis and hepatocellular carcinoma (HCC).
The pathogenesis of NAFLD is often rationalized as a ‘double-
hit’, whereby diet-induced hepatocellular lipid accumulation
presents the ‘first-hit’, followed by a ‘second-hit’ in which pro-
inflammatory mediators induce inflammation, hepatocellular
injury, and fibrosis [3]. Kupffer cell activation and recruitment
of monocytes into damaged liver facilitates pro-inflammatory
cytokine release that in turn promotes lipid accumulation,
increased inflammation and aberrant fibrosis. The post-transcrip-
tional gene regulatory mechanisms that integrate inflammation
and lipid dysregulation in NAFLD are currently poorly under-
stood but could offer significant therapeutic opportunity once
elucidated.
MicroRNAs (miRs) are small, non-coding, endogenous RNA
molecules (22 nucleotides long) that act as critical post-transcrip-
tional regulators of many biological processes. They function by
binding to complementary sequences in the 39UTRs of specific
target mRNAs, usually resulting in gene silencing [4]. Recently, a
role for miRNAs in liver disease has been proposed: hepatic
expression profiling has revealed temporal changes in miRNA
expression in human and murine NAFLD, and identified several
differentially expressed miRNAs including miR-21, miR-34a, and
miR-122 [5]. In addition, it has been shown that hepatic miR-155
expression was increased in murine models of NASH and HCC,
and its expression correlated with disease severity [6,7]. In line
with increased miR-155, the miR-155 target genes CCAAT/
enhancer-binding protein beta (Cebpb) and suppressor of cytokine
signaling 1 (Socs1) were decreased. MiR-155 is a multi-functional
miRNA known to regulate numerous biological processes
including hematopoiesis, inflammation, immunity,
atherosclerosis, and cancer (reviewed in [8]). However, the
functional role of miR-155 in liver homeostasis is unknown. Here
we report that absence of miR-155 in mice fed high fat diet was
associated with significantly increased hepatic steatosis and serum
VLDL/LDL cholesterol levels. miR-155 regulates cholesterol and
fatty acid metabolism pathways in liver by directly targeting liver
X receptor alpha (LXRa), a transcriptional regulator of many
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genes in liver lipid metabolism [9]. Thus, our data directly
implicate miR-155 in liver homeostasis and its deregulation as a
pivotal factor in the pathogenesis of fatty liver disease.
Experimental Procedures
Animal Experimentation
Male C57BL/6 wild-type (WT) mice and miR-1552/2 mice
(Jackson Labs) were bred in-house in a pathogen-free facility and
fed normal chow or high fat diet (HFD; 0.15% cholesterol and
21% lard, Special Diet Services) ad libitum from 6 weeks old. Male
ob/ob mice (Jackson Labs) were fed normal diet from 5 weeks old
for 4 weeks. All experiments were approved by the University of
Glasgow Animal Procedures and Ethics Committee and per-
formed in strict accordance with UK Home Office guidelines
under the Animals Scientific Procedures Act 1986. All efforts were
made to minimize animal suffering and the number of animals
used was kept to a minimum by the experimental design.
Insulin Tolerance Tests (ITT)
ITT were carried out 1-day before cull of mice. Briefly, mice
were fasted for 4 hrs (ITT), injected intraperitoneally with insulin
(0.75 U/kg, Sigma) in 25 mM Hepes. A tail vein blood sample
was taken before injection and 30, 60, and 90 minutes after
injection for determination of blood glucose using Accu-chek
Compact test strips (Roche Diagnostics).
Morphometric and Immunohistochemical Analysis of
Livers
The mice were killed after an overnight fast. Livers were fixed in
10% formalin for 24 hours or kept freshly frozen. Formalin-fixed
paraffin-embedded liver sections (5 mm) were stained with
hematoxylin and eosin (H&E). Oil red O staining was carried
out on frozen liver sections (10 mm). Immunohistochemistry was
performed using anti-mouse F4/80 (Serotec) for macrophages,
followed by incubation with the ImmPRESS reagent and
detection with DAB (Vector Laboratories).
Figure 1. Liver expression of miR-155 is increased in murine models of obesity. Expression of miR-155 by qRT-PCR in: (A) Tissues from 8-
week old WT mice fed normal chow (n= 3)(WAT: white adipose tissue); (B) Livers from WT mice fed either normal chow or HFD for 24 weeks; (C)
Livers from WT and ob/ob mice fed normal chow for 5 weeks. Data are Means 6 SEM, n = 3–5 mice/group. (D) Representative sections showing
localization of miR-155 in livers by in situ hybridization (purple stain, 40x magnification, scale bar 5 mm). Sections counterstained with nuclear red.
Scrambled oligo probe was used as a negative control (inset). (E) Quantification of miR-155 in situ staining in livers from WT mice fed either chow or
HFD for 24 weeks (n = 5–7/group). ** p,0.01 Mann-Whitney test. (F) Expression of miR-155 in bead-sorted CD11b+ macrophages and CD11b2 cells
from livers of WT mice fed HFD for 24 weeks (n = 3). *p,0.05 Student’s unpaired t-test.
doi:10.1371/journal.pone.0072324.g001
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In situ Hybridization on Paraffin-embedded Tissues
After de-paraffinization, sections were treated with proteinase-
K (5 mg/mL) for 30 min at 37uC. Hybridization with 5 nmol
Locked Nucleic Acid 59 and 39 digoxigenin (DIG)-labeled scra-
mble (AGAGCTCCCTTCAATCCAAA) or miR-155–specific
(TATCACAATTAGCATTAA) probes (both from Exiqon) was
performed at 48uC for 1 h. After hybridization, sections were
washed SSC (5x, 1x then 0.2x each for 2 washings of 5 mins) at
48uC and a final wash in 0.2x SSC at RT for 5 min. Next, sections
were blocked with DIG Wash and Blocking buffer (Roche) in a
Table 1. Association of liver weight with murine clinical parameters.
Chow HFD
Parameter WT miR-1552/2 WT miR-1552/2
Body weight (g) 35.0360.86 34.4860.63 39.1661.36 41.8961.74
Epididymal fat (g) 0.9460.04 0.7460.11 1.8860.19 1.7560.20
ALT (U/L) 4.2660.45 3.4260.53 5.6361.29 10.7861.97*
Total cholesterol (mg/dL) 64.0564.3 55.4364.65 93.1065.84 83.4168.78
VLDL/LDL cholesterol (mg/dL) 12.9260.83 13.4362.95 21.6761.70 33.2066.18*
HDL cholesterol (mg/dL) 26.3765.50 36.3165.05 61.2367.01 51.8069.11
Triglycerides (mg/dL) 52.8466.99 38.13619.8 87.0164.55 118.4634.4
Insulin (ng/ml) 3.3260.67 7.0161.73* 4.9860.78 10.0762.55*
Livers were collected from mice at 24 wk of age fed either normal chow or high fat diet (HFD). Alanine transaminase (ALT), cholesterol, triglyceride and insulin values
were determined in serum. Data are Means 6 SEM pooled from 2 independent experiments: n = 13–21 mice/group.
*p,0.05 Student’s unpaired t-test.
doi:10.1371/journal.pone.0072324.t001
Figure 2. miR-1552/2 mice are susceptible to hepatic steatosis. WT or miR-1552/2 mice were fed either normal chow or HFD and livers
examined at 24 weeks. (A) Liver weights (g). (B) Gross morphology. (C) Total cholesterol (TC), free cholesterol (FC) and cholesterol ester (CE)
measurements in liver (mg/mg of cell protein). (D) Triglyceride measurements in liver (mg/mg of cell protein). (E) Representative H&E, and Oil Red O
staining of the livers (40x magnification, scale bar 5 mm). Data are Means 6 SEM pooled from 2 independent experiments, n = 13–21 mice/group. **
p,0.01, *** p,0.001 Student’s unpaired t-test compared to WT fed HFD.
doi:10.1371/journal.pone.0072324.g002
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humidifying chamber for 15 min at RT. Slides then were
incubated with alkaline phosphatase-conjugated sheep anti-DIG
antibody (1:800; Roche) in blocking solution supplemented with
2% sheep serum for 1 h at RT. Sections were incubated nitro-blue
tetrazolium (NBT) and 5-bromo-4-chloro-39-indolyphosphate
(BCIP) solution (Roche) for 2 h at 30uC. To stop the reaction,
slides were washed twice for 5 min with buffer containing 50 mM
Tris-HCl, 150 mM NaCl, and 10 mM KCl. Nuclear counter-
staining was performed using Nuclear Fast Red (Vector). Liver
tissues were evaluated using a numerical score based on the
number of positive cells in the section (three different fields in each
section), with a score of 0 indicating no positive cells; 1 indicating
,10% positive cells; 2 indicting 10–50% positive cells; and 3
indicating .50% positive cells.
Liver Lipids
Lipids were extracted from 1 mg of tissue using Isopropanol at
4uC overnight in a rotating glass tube. After extraction the lipids
were dried with N2 and then resuspended in isopropanol. Protein
quantification was carried out using RC DC Protein Assay Kit II
(BioRad). Triglyceride and cholesterol content were measured
using kits from Wako Diagnostics according to the manufacturer’s
protocols.
Flow Cytometry
Livers were collagenase (C6885, Sigma) digested for 30 minutes
at 37uC with shaking and a single cell suspension prepared
following filtration through a 100 mm cell strainer. Cells were
resuspended in FACS buffer (PBS, 2% FCS, 2 mm EDTA) then
incubated with Fc-Block (BD Biosciences) for 15 minutes before
staining with F4/80-APC (eBioscience) and CD45-PE (BD
Biosciences) or isotype controls. Cells were analyzed on a BD
FACS Calibur with CellQuest Pro SoftwareTM.
Serum Analysis
Total serum cholesterol, VLDL/LDL and HDL, and triglyc-
eride levels (mg/dL) were measured by EnzyChromTM assay kits
(Universal Biologicals). Metabolic proteins were analyzed using the
mouse adipocyte kit (Insulin, Resistin, Leptin) (Millipore) on the
Bio-Plex 100 system (Bio-Rad). Alanine Transaminase (ALT)
levels were measured in serum using an ALT Activity Assay Kit
(Camridge Bioscience).
MACS Bead Selections
For macrophage isolation CD11b+ cells were selected by
labeling with CD11b beads (Miltenyi) and positively selected on
Figure 3. miR-1552/2 mice have altered expression of inflammatory and metabolic genes in liver. (A) FACS quantification of the %
CD45+F4/80+ macrophages in livers fed HFD and representative F4/80+ macrophage staining (brown) and isotype controls (inset) in liver (40x
magnification, scale bar 5 mm). qRT-PCR analysis of expression of inflammatory genes (Socs1, Il1b, Il6, Tnf, and Nos2) (B), and metabolic genes (Pck1,
Ppargc1a, Pparg, Cebpa, Cebpb, Hmgcr, Ldlr, Srebf1, Cd36, Cyp7a1, Fas, Acc, Fabp4, Ampk, Cpt1a, Crot) (C) relative to WT control. Data are Means6 SEM
pooled from 2 independent experiments, n = 3–5 mice/group. * p,0.05, ** p,0.01 Student’s unpaired t-test compared to WT fed HFD.
doi:10.1371/journal.pone.0072324.g003
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an AutoMACs separator. Macrophage populations were con-
firmed to contain .98% CD45+F4/80+ cells prior to further
experiments.
Quantitative PCR
Total RNA from frozen liver was prepared by tissue homog-
enization in Qiazol (Invitrogen) followed by purification with
miRNeasy kits (Qiagen). The miScript Reverse Transcription Kit
(Qiagen) was used for cDNA preparation. TaqMan Gene
Expression Assays (Applied Biosystems) or miScript primer assays
(Qiagen) were used for determination of gene expression. The
expression of U6B snRNA or TATA binding protein (TBP) was
used as endogenous controls and data analyzed on the
ABI7900HT machine with SDS 2.2 software. Data is presented
as RQ values (22DDCT) with expression relative to endogenous
control and WT control sample.
Microarray Analysis
Total RNA from frozen liver was prepared by homogenization
in Qiazol (Invitrogen) followed by purification with miRNeasy kits
(Qiagen). RNA quality and quantity was assessed on a Nanodrop
(Thermo Scientific) and Agilent 2100 Bioanalyzer. An Affymetrix
GeneChipH Mouse Gene 1.0 ST Array was performed using total
RNA from three independent biological replicates. The micro-
array data produced in this study is MIAME compliant (http://
www.mged.org/Workgroups/MIAME/miame.html) and it has
been submitted to the ArrayExpress database (www.ebi.ac.uk/
arrayexpress) under accession No E-MEXP-3932. CEL files were
analyzed using R and Bioconductor [10]. Quality control was
carried out using package arrayQualityMetrics [11] before and after
RMA pre-processing using the Oligo package [12]. One suspect
sample was flagged and removed from further analysis. Differen-
tial gene expression analysis was carried out using oneChannelGUI
[13] and Rank Product statistic [14], which is particularly suited to
small data sets. A pfp (predictor of false positive) value of 0.05 was
chosen to determine differentially expressed genes. Ingenuity
Pathway Analysis (IPA) was used for functional and canonical
pathway analysis. The significance of association between
differentially expressed genes and canonical pathways was
determined using Fisher’s exact test to test the probability that
the association between genes and pathway occurred by chance
alone. The P-value generated was then corrected with Benjamini-
Hochberg correction for multiple testing.
MiR-155 Target Prediction and Validation
MiR-155 target prediction was carried out using the algorithms
TargetScanHuman V6.2 (http://www.targetscan.org/vert_61/),
PicTar (http://pictar.mdc-berlin.de) and miRTarBase (http://
mirtarbase.mbc.nctu.edu.tw). We then compared predicted targets
and the miR-155 target database of IPA (TargetScan, Tarbase
targets and other literature based targets) with our transcriptomic
data to choose candidate genes for further validation (Table S3). In
order to validate the candidate miR-155 predicted targets,
luciferase reporter assays were carried out. Briefly, potential
miR-155 miRNA recognition elements (MREs) were amplified
from relevant genomic DNA using PfuUltra II (HS) (Agilent).
Primers (Table S4) were designed incorporating PmeI and SalI in
the forward and reverse primers respectively. Candidate MREs
were cloned into the same sites downstream of the Renilla
Luciferase gene in pmiRGLO (Promega). HEK293 cells were co-
transfected with 0.2 mg pmiRGLO containing potential miR-155
MREs and 40 nM miR155 mimic or scrambled mimic control,
using Attractene (Qiagen). Luciferase activity was measured 24 hrs
later using the Dual-GLO Luciferase assay system (Promega). The
Figure 4. Identification of miR-155 direct targets in liver. (A) Interaction map showing liver mRNA that are direct targets of miR-155 by
Ingenuity Pathway Analysis that shows genes involved in Lipid Metabolism, Molecular Transport, and Small Molecule Biochemistry. miR-155 direct
targets that are up-regulated in miR-1552/2 livers are marked in red. (B) Expression of the identified target genes Abcd2, Agtrap, Lpl, Nr1h3 (LXRa) and
Pla2g7 validated by qRT-PCR in WT vs miR-1552/2 livers fed HFD (n= 3). Expression is shown relative to WT control. *** p,0.001 Student’s unpaired t-
test.
doi:10.1371/journal.pone.0072324.g004
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miR-155 seed region of mouse Nr1h3 was mutated using
QuikChange Lightning kit (Agilent) and the primers:
Fw GAAGGAGAGAGCCTTGCGTAggatccAGGGAGAGT
C;
Rev GACTCTCCCTggatccTACGCAAGGCTCTCTCCTT
C.
Macrophage Transfection Experiments
CD11b+ cells from WT and miR-1552/2 livers were transfected
with miR-155 or control mimics (25 nM; Dharmacon: mmu-miR-
155: UUAAUGCUAAUUGUGAUAGGGGU; control mimic
cel-67: UCACAACCUCCUAGAAAGAGUAGA) or anti-mmu-
miR-155 (MIN0000165) or control anti-miR (1027271, both
25 nM, Qiagen) with N-Ter transfection reagent (Sigma). After
24 hours whole lysate was prepared using M-PER (Thermo
Scientific) lysis buffer. Total protein (10 mg) was ran on 10%
SDS Page gel followed by transfer to PVDF membrane and
incubation with rabbit anti-mouse/human LXRa (2 mg/ml;
Lifespan Biosciences) or anti-mouse/human b-actin (1 mg/ml,
Santa Cruz Biotechnology).
Statistical Analysis
All data are mean 6 standard error of mean (SEM). Statistics
were performed using unpaired Student’s t tests, Mann-Whitney
or ANOVA, with GraphPad Prism SoftwareH.
Results
Expression of Liver miR-155 is Increased in Murine
Models of Diet-induced Obesity
MiR-155 expression in normal liver is low in comparison to
other solid organs in 8-week old WT mice (Figure 1A), but was
upregulated under patho-physiological conditions. Quantitative
PCR demonstrated significantly higher hepatic expression of miR-
Figure 5. Identification of Nr1h3 (LXRa) as a miR-155 target gene. (A) Schematic showing alignment of mouse and human LXR 39UTR with
the miR155 seed region highlighted. (B) miR-155 binds directly to the 39UTR of mouse Nr1h3 (LXRa) mRNA. Murine pGLO-LXRa 39UTR luciferase
plasmids were co-transfected with miR-155 or scrambled (SCRAM) control mimic (40 nM) in HEK293 cells. Plasmids with a mutated 39UTR are shown
as pGLO-LXRa(mt). Luciferase activity was analyzed at 24 h. Data are Means 6 SEM, n = 3 from 2 independent experiments. (C) Expression of Nr1h3
(LXRa) in bead sorted CD11b+ macrophages and CD11b2 cells from livers of WT and miR-1552/2mice (n = 3). * p,0.05, ** p,0.01 Student’s unpaired
t-test. (D) Western blot for LXRa in CD11b+ cells isolated from WT or miR-1552/2 livers and transfected with control mimic (Cm), miR-155 mimic,
control inhibitor (Ci) or miR-155 inhibitor. b-actin is shown as a loading control. (E) Schematic diagram indicating the pathway of miR-155 inhibition
of LXRa-induced gene regulation of lipid accumulation during hepatic steatosis following a high fat diet (HFD).
doi:10.1371/journal.pone.0072324.g005
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155 in WT mice fed HFD (Figure 1B), and in ob/ob mice on
normal chow versus their respective controls (Figure 1C). Next we
mapped the expression pattern of miR-155 in liver by in situ
hybridization. Elevated miR-155 tissue expression was observed in
livers of mice fed HFD, paralleling PCR expression data
(Figure 1D and E). These data confirm and extend previous
studies showing that expression of miR-155 is increased in livers of
animal models of NAFLD [6,7].
To identify the cell lineage responsible for upregulated miR-155
expression, we purified hepatic CD11b+ macrophages. In WT
mice fed HFD for 24 weeks, miR-155 expression was higher in
CD11b+ macrophages compared to the CD11b2 fraction,
comprising of all other hepatic cell lineages (Figure 1F). These
data suggest that homeostatic effects of miR-155 in liver are likely
mediated by macrophages/Kupffer cells, and not by hepatocytes.
miR-1552/2 Mice are Susceptible to Hepatic Steatosis
Since the functional role of miR-155 in development of hepatic
steatosis associated with obesity is currently unknown, we next
investigated whether miR-155 could integrate inflammatory and
lipid signaling in liver in vivo, under conditions of diet-induced
obesity thereby resulting in hepatic steatosis. We first compared
WT and miR-1552/2 mice fed chow or HFD for 24 weeks.
Deficiency of miR-155 did not alter the final body weight of mice
at 24 weeks (Table 1), but mean liver weight was increased by 30%
in miR-1552/2 mice fed HFD (Figure 2A). The weight of
epididymal fat pads, did not differ between groups, indicating a
selective effect on liver (Table 1). Changes in the gross appearance
of livers from miR-1552/2 mice were evident with yellow/brown
coloration and visible surface nodules (Figure 2B). Liver triglyc-
eride (Figure 2C) and total cholesterol (TC), free cholesterol (FC)
and cholesterol ester (CE) levels were significantly increased in
livers of miR-1552/2 mice vs WT fed HFD (Figure 2D).
Abundant lipid droplets were observed in livers of WT and
miR-1552/2 mice fed HFD (Figure 2E). Serum levels of the
enzyme ALT, indicative of liver damage, were increased in miR-
1552/2 mice fed HFD (Table 1). Furthermore, serum levels of
VLDL/LDL cholesterol were significantly higher in HFD-fed
miR-1552/2 mice vs WT. Total cholesterol, HDL cholesterol and
triglyceride levels in serum did not significantly differ between WT
and miR-1552/2 mice (Table 1).
Next, to investigate whether glucose and insulin sensitivity were
altered in the miR-1552/2 mice we measured fasting glucose and
insulin, and carried out an insulin tolerance test (ITT) in the mice
at week 24. Serum insulin levels were significantly higher in both
chow and HFD-fed miR-1552/2 mice (Table 1). However, fasting
glucose and ITT were similar between WT and miR-1552/2 mice
(Figure S1).
Altered Inflammatory and Metabolic Gene Expression in
Livers of miR-1552/2 Mice
To address the molecular mechanisms of enhanced hepatic
steatosis in miR-1552/2 mice, we examined expression of various
inflammatory and metabolic markers in livers and serum of HFD-
fed mice. First, we assessed macrophage content of livers using the
markers CD45 (pan-leukocytes) and F4/80 (macrophages). Flow
cytometric and immunohistochemical analysis demonstrated that
CD45+F4/80+ macrophages did not differ in number between
WT and miR-1552/2 livers (Figure 3A). Therefore, we assessed
the change in expression of liver inflammatory genes. Expression
of the miR-155 validated target gene Socs1 was significantly
upregulated in miR-1552/2 livers [15] (Figure 3B). We also found
significantly increased expression in the genes for inducible nitric
oxide synthase (Nos2), no change in interleukin-6 (Il6) or tumor
necrosis factor a (Tnf), but reduced expression of interleukin-1b
(Il1b) in miR-1552/2 vs WT mice (Figure 3B).
We then examined the expression of key genes already known to
be involved in liver functions. Interestingly, the expression of genes
involved in gluconeogenesis (Pck1, Cebpa), cholesterol uptake (Cd36)
and fatty acid synthesis (Fasn, Fabp4) were significantly increased in
HFD-fed livers of miR-1552/2 mice vs WT mice (Figure 3C),
indicating that they could be responsible, or contribute to the
observed phenotype in miR-1552/2 mice. Several other key genes
involved in lipid and glucose metabolism were not significantly
different (Ppparc1a, Pparg, Cebpb, Srebf1, Cyp7a1, Acc, Ampk, Cpt1a,
Crot), or were significantly reduced (Hmgcr, and Ldlr) in miR-1552/
2 mice on HFD (Figure 3C). In summary, deletion of miR-155
significantly alters the expression of selected inflammatory and
metabolic pathways within liver.
LXRa (Nr1h3): A Lipid Pathway Transcriptional Regulator
is a Direct Target of miR-155 in Liver
To gain further insight into the mechanisms underlying such
pleiotropic effects of miR-155 in liver we performed a microarray
analysis comparing livers from HFD-fed WT and miR-1552/2
mice. Using the Rank Products method out of ,28,853 probesets
analyzed we found 573 probeset IDs that were differentially
expressed in miR-1552/2 vs. WT livers (pfp,0.05). These
mapped to 336 genes, of which 286 were upregulated and 50
were downregulated in miR-1552/2 livers (Table S1). In order to
identify molecular pathways altered within the dataset, the list of
differentially regulated genes was uploaded to Ingenuity Pathway
Analysis (IPA) software and a Core analysis carried out. Lipid
metabolism and cell cycle networks were significantly enriched in
livers from miR-1552/2 mice, as were networks involved with
hepatocellular carcinoma and liver steatosis. Pathway analysis
identified the LXR/RXR pathway as the top canonical pathway
upregulated in livers from miR-1552/2 mice (Table S2).
Next, in order to identify the direct molecular mechanism
responsible for miR-155 action, we combined bioinformatics and
transcriptomic profiling of miR-1552/2 livers as follows. Firstly,
we identified putative binding sites for miR-155 in the 39UTR of
440 genes (TargetScanHuman v6.2) that were also conserved
across species. By comparing this list with our transcriptomic data
(Table S1) in Ingenuity Pathway Analysis, 7 genes emerged as
potential direct miR-155 target genes that were implicated in liver
metabolism (Abcd2, Lpl, Pla2g7, Agtrap, Msr1, Nr1h3 and Ywhae) for
further validation (Figure 4A, Tables S3 & S4). We confirmed by
qPCR that 4 of these potential targets were strongly upregulated in
miR-1552/2 livers (Figure 4B). Next, we tested the direct
interactions of miR-155 with 39UTR of these mRNAs in luciferase
reporter assays. Among the potential targets examined, Nr1h3
(LXRa) was identified as a direct target of mouse miR-155 and the
binding site appears to be conserved in humans (Figure 5A). The
evidence for this is shown in Figure 5B - significant inhibition of
luciferase activity was observed in HEK293 cells co-transfected
with plasmids for the 39UTR of mouse Nr1h3 (LXRa) and the
corresponding miR-155 mimic (pGLO-LXRa+miR155) versus
scramble control mimic (pGLO-LXRa+SCRAM). Mutation of the
Nr1h3 (LXR a) miR-155 target sequence prevented downregula-
tion of luciferase activity by miR-155 mimic (pGLO-LXRa(mt)+-
miR155) (Figure 5B), thus confirming Nr1h3 (LXRa) as a bonafide
miR-155 target gene. To identify the cell type where the miR-
155/LXRa pathway is operating in the liver, we examined the
expression of LXRa in CD11b+ and CD11b2 hepatic fractions.
Nr1h3 (LXRa) was upregulated only in CD11b+ macrophages, and
not in CD11b2 cells, purified from livers of miR-1552/2 mice
compared WT control (Figure 5C). These data suggest that the
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effect of miR-155 absence on Nr1h3 (LXRa) upregulation may be
taking place in Kupffer cells, and not in other liver cell lineages.
To investigate this further we isolated CD11b+ cells from liver of
WT and miR-1552/2 mice and transfected them with control or
miR-155 mimics, control or miR-155 inhibitors (Figure 5D).
Western blotting for LXRa demonstrated that transfection with a
miR-155 inhibitor in CD11b+ cells from WT livers resulted in an
upregulation of LXRa protein. In contrast, transfection with a
miR-155 mimic in CD11b+ cells from miR-1552/2 livers resulted
in downregulation of LXRa.
In addition, we found that the LXR-responsive genes Fasn, Cd36
and Lpl (Figure 3C, Figure 4B) were upregulated in livers of miR-
1552/2 mice but not all LXRa target genes were altered in the
livers of miR-1552/2 mice, despite changes in LXRa expression.
For example, Cyp7a1 and Srebf1 did not change (Figure 3C).
However, a loss of repression of LXRa expression in miR-1552/2
mice does represent a plausible mechanism by which the hepatic
phenotype is induced (Figure 5E).
Using luciferase reporter assays the other predicted miR-155
targets (Abcd2, Lpl, Pla2g7, Agtrap, Msr1 or Ywhae) could not be
validated as direct targets of miR-155 (Figure S2). Therefore,
upregulation of these genes in livers of miR-1552/2 mice is likely
to be a result of secondary effects of deregulation of the miR-155/
LXRa pathway.
Discussion
There is growing evidence for a role of miRNAs in the
pathogenesis of many liver diseases [5], and recent studies have
shown that expression of miR-155 is increased in hepatitis C virus
infection [16], alcoholic liver disease [17], HCC [18], and in
NAFLD [6,7]. However, it has remained unclear whether miR-
155 functionally contributes to development of liver disease. Here
we report for the first time that absence of miR-155 in mice fed
HFD for 6 months is associated with a significant increase in
hepatic steatosis, suggesting a protective role of miR-155 in liver
lipid metabolism.
Our data demonstrate that miR-155 was upregulated in livers of
obese mice, and that this increased expression was primarily
detected in CD11b+ macrophage cells. Inflammatory mediators
(e.g. LPS, TNFa) have previously been shown to increase
expression of miR-155 in macrophages and fibroblasts [19,20],
thus given the strong pro-inflammatory environment within the
steatotic liver it is likely that inflammatory signals can upregulate
miR-155. Furthermore, previous studies have shown that diet-
induced activation of NF-kB is critical mediator regulating
expression of miR-155 [6]. In addition, we would like to speculate
that lipids themselves might directly regulate expression of miR-
155. Analysis of the human and mouse miR-155 promoter
(MATInspector) reveals multiple binding sites for LXR/RXR
heterodimers indicating that miR-155 could be directly induced by
oxysterols generated as part of a HFD. This may comprise a
counterbalance mechanism, thus preventing excessive liver lipid
overload and warrants further investigation.
Although miR-155 is generally considered a pro-inflammatory
miRNA in macrophages during chronic inflammatory diseases
such as rheumatoid arthritis [19,20,21], the data herein suggests
that increased expression of miR-155 in obese liver macrophages
is an important part of a protective negative regulatory feedback
mechanism aimed at limiting disease progression by preventing an
excessive lipid accumulation in the liver. In fact, in the context of
lipid and inflammatory signaling in macrophages conflicting data
has been obtained for miR-155. For example, miR-155 induced
the chemokine CCL2 in macrophages stimulated with mildly
oxLDL (moxLDL) and IFN-c, but not highly oxidized LDL, via
direct suppression of Bcl6, a transcription factor that counter-
regulates NF-kB activation, thus indicating pro-inflammatory
actions in the context of atherosclerotic plaque macrophages [22].
However, other studies show contrasting anti-inflammatory effects
of miR-155 in lipid-laden macrophages. Silencing of endogenous
miR-155 in macrophages significantly enhanced oxLDL-induced
lipid uptake, up-regulated the expression of scavenger receptors
(LOX-1, CD36 and CD68), and promoted the release of several
cytokines including IL-6, -8, and TNF-a [23]. Chen et al
demonstrated similar findings showing that inhibition of miR-
155 expression significantly induced lipid uptake and over-
expression miR-155 can decrease the lipid uptake in PMA-
differentiated THP-1 cells and dendritic cells [24]. Conflicting
data has also been obtained using in vivo murine atherosclerosis
models where one study showed that haematopoietic deficiency of
miR-155 in LDLR2/2 mice led to enhanced early atherosclerosis
due to an increase in neutrophil migration [25], while another
study more recently demonstrated that haematopoietic deficiency
of miR-155 in ApoE2/2 mice led to decreased atherosclerosis via
inhibition of Bcl6 in macrophages [22]. Thus, it is clear that miR-
155 can have different effects on macrophage lipid uptake and
inflammatory signals in different settings. In fact, we observe a
relative minor difference in inflammatory cytokines between WT
and miR-1552/2 mice on HFD (a decrease in IL-1b, no change in
IL-6 and TNFa) suggesting miR-155 preferentially regulates lipid
metabolism pathways in these cells. This may reflect a role in fine-
tuning of macrophage function that is context, activation status
and tissue dependent on the availability of mRNA targets, and
other miR binding and competing RNAs in the macrophage [26].
MiRNAs are critical regulators of many pathways by negatively
targeting expression of multiple genes. Our studies suggest that the
LXR and LXR-regulated genes are highly induced in livers, and
liver macrophages, from miR-1552/2 mice, and using luciferase
assays we show that LXRa is a direct molecular target of miR-155.
LXRs are a class of nuclear receptors activated by endogenous
oxysterols [9], and previous studies have shown that the LXRa
gene is upregulated in liver of NAFLD and Hepatitis C patients
who had steatosis [27]. Furthermore, several previous studies have
shown that treatment of mice with pharmacological LXR agonists
induces fatty liver [28]. This appears to be mediated via an
induction of fatty acid synthesis and the scavenger receptor CD36,
contributing to hepatic lipid accumulation [29]. Concordantly,
both of these genes are also upregulated in miR-1552/2 livers in
our study. Thus, we speculate that LXRa upregulation in the
absence of repression by miR-155 leads to excessive lipid
accumulation in liver. However, not all LXRa target genes were
altered in miR-1552/2 livers, despite changes in LXRa expression
(e.g. Cyp7a1 and Srebp1). We cannot exclude the possibility that
these genes may be altered at other time points in the model and
thus contribute to the observed phenotype. Furthermore, miRNAs
are thought to be involved in fine-tuning pathways rather than
strong regulation, and do so most likely as part of a composite
regulatory network. Thus, we speculate that the magnitude of
depression of LXRa in miR-1552/2 is able to activate some but
not all LXR dependent pathways.
Recent studies also suggest that miR-155 may have metabolic
effects beyond liver. Expression of miR-155 in sub-cutaneous fat
biopsies was significantly higher in samples from normal glucose
control subjects as compared to those with T2D [30]. In cell-
based experiments incubation of 3T3-L1 adipocytes with insulin
resulted in a significant decrease in miR-155 [31]. Furthermore,
expression of miR-155 is decreased during adipogenesis in vitro
and over-expression of miR-155 inhibited expression of PPARc
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and cEBPa, thus suggesting that miR-155 acts as a negative
regulator of adipogenesis [32]. Finally, molecular studies showed
that miR-155 could directly target proteins that were implicated
in metabolism. For example, miR-155 inhibits translation of c-
EBPb (protein involved in early adipogenesis) and SOCS-1
(inhibitor of insulin signaling) in macrophages [15,33], thus
indicating a potential regulatory role of miR-155 in other
metabolic pathways [23]. In fact, we observed a strong increase
in Socs1 expression in livers of miR-1552/2 mice suggesting the
presence of functional interaction between miR-155 and Socs1 in
liver. Given the potent role of Socs1 in inhibiting insulin signaling,
it is likely that de-repression of Socs1 in miR-1552/2 livers is
responsible for an increase in the circulating insulin levels.
Therefore, it was surprising that the insulin tolerance was not
altered in the miR-1552/2 mice. However, this may be a
reflection of the model of diet-induced obesity used, as it is not a
model of type 2 diabetes. Or it may be a result of the time point
the insulin tolerance test was carried out when other compen-
satory pathways may have been initiated. A more detailed
analysis of glucose responses over several weeks following
inhibition of miR-155 is warranted in future studies in mouse
models of diabetes. In addition, strong up-regulation of Nos2
expression in miR-1552/2 liver was detected. In contrast to
endothelial NOS (Nos3) [34], Nos2 is not predicted to be targeted
by miR-155 (TargetScan), and LXR has previously been
implicated in transrepression of Nos2 rather than its activation
[35]. Thus, altered Nos2 expression is likely to be simply a
consequence of fatty liver pathology in these mice.
In summary, we have shown that miR-155 has a novel
regulatory role as an important regulator of cholesterol and lipid
metabolism, operating at least in liver via the LXRa pathway.
Increased expression of miR-155 in models of NAFLD likely
plays a critical homeostatic role designed to prevent excessive
lipid accumulation in livers that can ultimately lead to liver
damage. Future studies determining how miR-155 may interact
with lipid, fibrosis and inflammatory pathways in liver (and
other metabolic tissues) are warranted and could offer new
insights into the pathogenesis of hepatic steatosis and type 2
diabetes.
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Figure S1 Absence of miR-155 does not affect fasting
glucose levels or responses in an Insulin Tolerance Test.
(A) Fasting glucose (mmol/L) and (B) insulin tolerance tests at
week 24 in WT or miR-1552/2 mice fed either chow or HFD.
Data are Means 6 SEM pooled from 2 independent experiments,
n = 13–21 mice/group.
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Figure S2 miR-155 does not target the 39UTR of Abcd2,
Lpl, Pla2g7, Agtrap, Msr1 or Ywhae mRNAs. Mouse
pGLO-(gene of interest) 39UTR luciferase plasmids were co-
transfected with miR-155 or scrambled (SCRAM) control mimic
(40 nM) in HEK293 cells. Luciferase activity was analyzed at
24 h. Data are Means 6 SEM, n= 3 from 2 independent
experiments.
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Table S1 List of differentially expressed genes obtained
by microarray analysis of livers fromWT vs miR-1552/2
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